126 related articles for article (PubMed ID: 20837664)
21. Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage.
Bahassi el M; Myer DL; McKenney RJ; Hennigan RF; Stambrook PJ
Mutat Res; 2006 Apr; 596(1-2):166-76. PubMed ID: 16481012
[TBL] [Abstract][Full Text] [Related]
22. Role for ATM in DNA damage-induced phosphorylation of BRCA1.
Gatei M; Scott SP; Filippovitch I; Soronika N; Lavin MF; Weber B; Khanna KK
Cancer Res; 2000 Jun; 60(12):3299-304. PubMed ID: 10866324
[TBL] [Abstract][Full Text] [Related]
23. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways.
Tauchi T; Shin-Ya K; Sashida G; Sumi M; Nakajima A; Shimamoto T; Ohyashiki JH; Ohyashiki K
Oncogene; 2003 Aug; 22(34):5338-47. PubMed ID: 12917635
[TBL] [Abstract][Full Text] [Related]
24. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
25. Identifying inhibitors of ATM and ATR kinase activities.
Sarkaria JN
Methods Mol Med; 2003; 85():49-56. PubMed ID: 12710196
[No Abstract] [Full Text] [Related]
26. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
Hu Y; Bobb D; Lu Y; He J; Dome JS
Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
[TBL] [Abstract][Full Text] [Related]
27. MST-312 Alters Telomere Dynamics, Gene Expression Profiles and Growth in Human Breast Cancer Cells.
Gurung RL; Lim SN; Low GK; Hande MP
J Nutrigenet Nutrigenomics; 2014; 7(4-6):283-98. PubMed ID: 26022559
[TBL] [Abstract][Full Text] [Related]
28. Transient Telomerase Inhibition with Imetelstat Impacts DNA Damage Signals and Cell-Cycle Kinetics.
Thompson CAH; Gu A; Yang SY; Mathew V; Fleisig HB; Wong JMY
Mol Cancer Res; 2018 Aug; 16(8):1215-1225. PubMed ID: 29759988
[TBL] [Abstract][Full Text] [Related]
29. Proteomics success story. Novel biomarkers for DNA damage response pathways: insights and applications for cancer therapy.
O'Connor M
Proteomics; 2006 Sep; 6 Suppl 2():69-71. PubMed ID: 17031802
[No Abstract] [Full Text] [Related]
30. Emerging cancer therapeutic opportunities target DNA-repair systems.
Ding J; Miao ZH; Meng LH; Geng MY
Trends Pharmacol Sci; 2006 Jun; 27(6):338-44. PubMed ID: 16697054
[TBL] [Abstract][Full Text] [Related]
31. Important differences between topoisomerase-I and -II targeting agents.
Banerji S; Los M
Cancer Biol Ther; 2006 Aug; 5(8):965-6. PubMed ID: 16969072
[No Abstract] [Full Text] [Related]
32. A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers.
Hocke S; Guo Y; Job A; Orth M; Ziesch A; Lauber K; De Toni EN; Gress TM; Herbst A; Göke B; Gallmeier E
Oncotarget; 2016 Feb; 7(6):7080-95. PubMed ID: 26755646
[TBL] [Abstract][Full Text] [Related]
33. Telomerase Inhibitor TMPyP4 Alters Adhesion and Migration of Breast-Cancer Cells MCF7 and MDA-MB-231.
Konieczna N; Romaniuk-Drapała A; Lisiak N; Totoń E; Paszel-Jaworska A; Kaczmarek M; Rubiś B
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151281
[TBL] [Abstract][Full Text] [Related]
34. DNA repair inhibition and cancer therapy.
Martin NM
J Photochem Photobiol B; 2001 Oct; 63(1-3):162-70. PubMed ID: 11684463
[TBL] [Abstract][Full Text] [Related]
35. The effects of a telomere destabilizing agent on cancer cell-cycle dynamics--integrated modelling and experiments.
Hirt BV; Wattis JA; Preston SP; Laughton CA
J Theor Biol; 2012 Feb; 295():9-22. PubMed ID: 22108242
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones.
Lee CC; Huang KF; Chang DM; Hsu JJ; Huang FC; Shih KN; Chen CL; Chen TC; Chen RH; Lin JJ; Huang HS
Eur J Med Chem; 2012 Apr; 50():102-12. PubMed ID: 22357112
[TBL] [Abstract][Full Text] [Related]
37. Berberine Inhibits Telomerase Activity and Induces Cell Cycle Arrest and Telomere Erosion in Colorectal Cancer Cell Line, HCT 116.
Samad MA; Saiman MZ; Abdul Majid N; Karsani SA; Yaacob JS
Molecules; 2021 Jan; 26(2):. PubMed ID: 33450878
[TBL] [Abstract][Full Text] [Related]
38. A Combination of δ-Tocotrienol and Ferulic Acid Synergistically Inhibits Telomerase Activity in DLD-1 Human Colorectal Adenocarcinoma Cells.
Eitsuka T; Tatewaki N; Nishida H; Nakagawa K; Miyazawa T
J Nutr Sci Vitaminol (Tokyo); 2016; 62(5):281-287. PubMed ID: 27928113
[TBL] [Abstract][Full Text] [Related]
39. Dual mechanisms for telomerase inhibition in DLD-1 human colorectal adenocarcinoma cells by polyunsaturated fatty acids.
Eitsuka T; Nakagawa K; Miyazawa T
Biofactors; 2004; 21(1-4):19-21. PubMed ID: 15630164
[TBL] [Abstract][Full Text] [Related]
40. Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival.
Wilsker D; Bunz F
Mol Cancer Ther; 2007 Apr; 6(4):1406-13. PubMed ID: 17431119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
